AU2002238532A1 - Tripeptide derivatives for the treatment of postlesional diseases of the nervous system - Google Patents

Tripeptide derivatives for the treatment of postlesional diseases of the nervous system

Info

Publication number
AU2002238532A1
AU2002238532A1 AU2002238532A AU2002238532A AU2002238532A1 AU 2002238532 A1 AU2002238532 A1 AU 2002238532A1 AU 2002238532 A AU2002238532 A AU 2002238532A AU 2002238532 A AU2002238532 A AU 2002238532A AU 2002238532 A1 AU2002238532 A1 AU 2002238532A1
Authority
AU
Australia
Prior art keywords
sub
alkoxy
alkyl
residue
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002238532A
Other languages
English (en)
Inventor
Jacques Gonella
Jean-Marie Grumel
Jean Rapin
Hans Klaus Witzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TELL PHARM AG
Original Assignee
TELL PHARM AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TELL PHARM AG filed Critical TELL PHARM AG
Publication of AU2002238532A1 publication Critical patent/AU2002238532A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2002238532A 2001-02-05 2002-02-05 Tripeptide derivatives for the treatment of postlesional diseases of the nervous system Abandoned AU2002238532A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10105040.2 2001-02-05
DE10105040A DE10105040A1 (de) 2001-02-05 2001-02-05 Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
PCT/EP2002/001182 WO2002062372A2 (en) 2001-02-05 2002-02-05 Tripeptide derivatives for the treatment of postlesional diseases of the nervous system

Publications (1)

Publication Number Publication Date
AU2002238532A1 true AU2002238532A1 (en) 2002-08-19

Family

ID=7672833

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002238532A Abandoned AU2002238532A1 (en) 2001-02-05 2002-02-05 Tripeptide derivatives for the treatment of postlesional diseases of the nervous system

Country Status (9)

Country Link
US (1) US7163922B2 (enExample)
EP (1) EP1390055B1 (enExample)
JP (1) JP2004526701A (enExample)
AT (1) ATE310529T1 (enExample)
AU (1) AU2002238532A1 (enExample)
DE (2) DE10105040A1 (enExample)
DK (1) DK1390055T3 (enExample)
ES (1) ES2250617T3 (enExample)
WO (1) WO2002062372A2 (enExample)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU599809B2 (en) * 1987-05-20 1990-07-26 Zambon Group S.P.A. Isoxazoles with nootropic activity
CA1323301C (en) 1987-06-05 1993-10-19 Alan I. Faden Thyrotropin-releasing hormone analogs in cns injury
FR2622581B1 (fr) * 1987-11-03 1990-02-16 Inorgan Sa Rech Develop Pharm Nouveaux derives de l-proline, leur preparation et leurs applications biologiques
HU904967D0 (en) * 1988-04-22 1991-01-28 Hoechst Ag Process for producing new azabicyclo(3.3.o)octane-3-carboxylic acid-octylesther derivatives
DE4007869A1 (de) 1990-03-13 1991-09-19 Merck Patent Gmbh Aminosaeurederivate
JPH045240A (ja) 1990-04-20 1992-01-09 Taisho Pharmaceut Co Ltd 抗痴呆剤
WO1992011850A2 (en) 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
WO1992013549A1 (en) * 1991-02-07 1992-08-20 Research Corporation Technologies, Inc. Inhibition of cell proliferation by hydrophobic peptides
US6235929B1 (en) * 1991-12-27 2001-05-22 Georgia Tech Research Corporation Tripeptide α-ketoamides
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5834029A (en) * 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
WO1996041638A1 (en) 1995-06-13 1996-12-27 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative diseases
US5840838A (en) * 1996-02-29 1998-11-24 University Of Kentucky Research Foundation Process for enhancing the activity of amyloid β peptides
EP0929313A4 (en) 1996-10-04 2004-04-21 Auckland Uniservices Ltd REGULATION OF NEURAL ENZYMS
JP4727770B2 (ja) * 1997-09-26 2011-07-20 カルピス株式会社 尿中カテコールアミン低下、尿中ノルアドレナリン低下、尿中ドーパミン低下及びFischer比低下の少なくとも1つの軽減剤
US6080848A (en) * 1998-05-01 2000-06-27 Incyte Pharmaceuticals, Inc. Human brain associated protein
US6379691B1 (en) * 1998-09-29 2002-04-30 Medtronic/Ave, Inc. Uses for medical devices having a lubricious, nitric oxide-releasing coating
AU1574701A (en) * 1999-10-22 2001-04-30 Wrair Walter Reed Army Institute Of Research A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
JP4633876B2 (ja) * 1999-11-11 2011-02-16 カルピス株式会社 トリペプチドの製造方法
AU2001247334A1 (en) 2000-03-10 2001-09-24 Monsanto Company Novel peptides with anti-hypertensive activity
DE10105041A1 (de) * 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
DE10105038B4 (de) * 2001-02-05 2005-07-07 Neurotell Ag Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems

Also Published As

Publication number Publication date
DE10105040A1 (de) 2002-08-14
US7163922B2 (en) 2007-01-16
US20050101539A1 (en) 2005-05-12
EP1390055A2 (en) 2004-02-25
EP1390055B1 (en) 2005-11-23
DE60207550D1 (de) 2005-12-29
ATE310529T1 (de) 2005-12-15
WO2002062372A3 (en) 2004-01-08
JP2004526701A (ja) 2004-09-02
DE60207550T2 (de) 2006-08-10
ES2250617T3 (es) 2006-04-16
DK1390055T3 (da) 2006-01-09
WO2002062372A2 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
AU633913B2 (en) Novel tnf-inhibit proteins and their preparation
CY1107990T1 (el) Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων
HUP0000492A1 (hu) N-(Aril/heteroaril-acetil)-aminosav-észterek, azokat tartalmazó gyógyászati készítmények, valamint módszerek béta-amiloid fehérje képződése és felszabadulása gátlására e vegyületek felhasználásával
AU2003264514A1 (en) Wt1 substitution peptides
DE69912952D1 (en) Cyclosporine
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO2003048190A3 (en) Acyclovir-peptide analogs
WO2002018321A3 (en) Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
NO941151L (no) Lineære adhesjonsinhibitorer
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
WO2002024213A3 (en) Improved protocol for paracentesis
WO2002062373A3 (en) Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system
DE3569541D1 (en) Pharmacologically active peptides
AU666586B2 (en) Cyclopeptides
ATE310529T1 (de) Tripeptidderivate zur behandlung von postläsionalen krankheiten des nervensystems
WO2004046178A3 (en) Shrew paralytic peptide for use in neuromuscular therapy
EP1908781A3 (en) Modulation of immune response and methods based thereon
YU48997A (sh) Novi biološki aktivni proteini, njihove farmaceutske smeše i postupak za njihovo dobijanje
WO2001064715A3 (en) Memno peptides, a process for their preparation and their use
RU93050068A (ru) Циклопептиды, способ их получения, фармацевтические композиции и способ их получения, способ лечения
CA1284550C (en) Retro-inverso analogs of the bradykinin potentiating peptide bpp*in5a*xx
WO2002083729A3 (en) Polypeptides derived from amyloid precursor peptide (app) and their uses
AU2003264940A1 (en) Pyrazole derivatives and their use as therapeutic agents for hiv mediated diseases
CA2216704A1 (en) Novel peptides and remedy for bone diseases containing the same as active ingredient
YU63402A (sh) Memno peptidi, postupak za njihovo pripremanje i njihova primena

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase